Antibodies for
Immunohistochemistry
CEA (CEA31)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45194 IMPATH CEA RTU M (CEA31)
50 Tests
44258 CEA RTU M (CEA31)
7 ml Ready To Use
44537 CEA 0,1 M (CEA31)
100 µl liquid Concentrated
44538 CEA 1 M (CEA31)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Colon adenocarcinoma, Colon
mucosa
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Anti-CEA is employed essentially as a tool to assist in the distinction between adenocarcinoma and epithelioid malignant mesotheliomas, along
with other markers such as those against calretinin, CK 5&6, CD15, HBME-1, MOC-31, and Ber-EP4. Another suggested use of anti-CEA is
to immunophenotype various metastatic adenocarcinomas as a means of identifying their origin within a panel of different markers. Anti-CEA
positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and
endocervix. Polyclonal anti-CEA is useful in staining hepatocellular carcinoma in a canalicular pattern.
Liver: Malignant vs. Benign
mCEA
pCEA Hep-Par1 Glypican-3 CD34
p53
AFP
A1AT
TTF-1
Hepatocellular Carcinoma
-
+
+
+
+
+
-/+
-/+
+
(cytoplasmic)
Hepatoblastoma
-
+
+
+
-
+
+
+
-
Benign Liver Nodules
-
-
+
-
-
-
-
+/-
+
(cytoplasmic)
Pleura: Adenocarcinoma vs. Mesothelioma
CEA Calretinin CK 5&6 D2-40
WT1 Caldesmon TAG-72 Ep-CAM E-cadherin TTF-1
Adenocarcinoma
+
-
-
-
-
-
+
+
+
+
Mesothelioma
-
+
+
+
+
+
-
-
-
-
Reference
1. Abutaily AS, et al. J Clin Pathol. 2002 Sep; 55(9):662-8.
2. Bhatnagar J, et al. Anticancer Res. 2002 May-Jun; 22(3):1849-57.
86
